Objective To investigate the quality of life effects of mizolastine in patients with intermittent allergic rhinitis. Methods In the study, 213 patients with intermittent allergic rhinitis were randomly assigned into two groups: mizolastine group (108 cases) and cetirizine group (105 cases). The severity of allergic rhinitis was rated according to visual analogue scale (VAS). Medical outcome study short form 36 items health survey (MOS SF36) questionnaire scores were used and then statistical analysis was made. Results 7 days after administration, there was significant difference in the VAS scores between the two groups (P<0.05). 2 weeks after administration, the differences in VAS or SF 36 scores between the two groups were statistical insignificant (P>0.05). Conclusion Mizolastine can relieve the symptoms of the patients with intermittent allergic rhinitis promptly, and therefore improve their quality of life.